- 全部删除
您的购物车当前为空
Visugromab(CTL-002)是一种靶向并中和GDF-15的单克隆抗体。Visugromab与抗PD1抗体Nivolumab 具有协同抗癌活性,可用于PD-1/PD-L1复发/难治性转移性实体瘤。
Visugromab(CTL-002)是一种靶向并中和GDF-15的单克隆抗体。Visugromab与抗PD1抗体Nivolumab 具有协同抗癌活性,可用于PD-1/PD-L1复发/难治性转移性实体瘤。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 2,480 | In stock | |
| 5 mg | ¥ 6,470 | In stock | |
| 10 mg | ¥ 8,720 | In stock | |
| 25 mg | ¥ 12,900 | In stock |
Visugromab 相关产品
| 产品描述 | Visugromab (CTL-002) is a monoclonal antibody that targets and neutralises GDF-15. Visugromab exhibits synergistic anticancer activity with the anti-PD1 antibody Nivolumab, making it suitable for PD-1/PD-L1 recurrent/refractory metastatic solid tumours. |
| 体内活性 | 在食蟹猴临床前毒理学研究中,Visugromab(最高剂量100 mg/kg,每周)并未展现出任何毒性迹象。[2] |
| 别名 | 维舒古单抗, CTL-002, CTL002 |
| CAS No. | 2556646-63-8 |
| 颜色 | Transparent |
| 物理性状 | Liquid |
| 存储 | store at low temperature | store at -20°C | Shipping with blue ice/Shipping at ambient temperature. |
评论内容